BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 27436101)

  • 1. Tumor infiltrating lymphocytes and PD-L1 expression in brain metastases of small cell lung cancer (SCLC).
    Berghoff AS; Ricken G; Wilhelm D; Rajky O; Widhalm G; Dieckmann K; Birner P; Bartsch R; Preusser M
    J Neurooncol; 2016 Oct; 130(1):19-29. PubMed ID: 27436101
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PD-L1 expression correlates with tumor-infiltrating lymphocytes and better prognosis in patients with HPV-negative head and neck squamous cell carcinomas.
    Sanchez-Canteli M; Granda-Díaz R; Del Rio-Ibisate N; Allonca E; López-Alvarez F; Agorreta J; Garmendia I; Montuenga LM; García-Pedrero JM; Rodrigo JP
    Cancer Immunol Immunother; 2020 Oct; 69(10):2089-2100. PubMed ID: 32448984
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Image Analysis-based Assessment of PD-L1 and Tumor-Associated Immune Cells Density Supports Distinct Intratumoral Microenvironment Groups in Non-small Cell Lung Carcinoma Patients.
    Parra ER; Behrens C; Rodriguez-Canales J; Lin H; Mino B; Blando J; Zhang J; Gibbons DL; Heymach JV; Sepesi B; Swisher SG; Weissferdt A; Kalhor N; Izzo J; Kadara H; Moran C; Lee JJ; Wistuba II
    Clin Cancer Res; 2016 Dec; 22(24):6278-6289. PubMed ID: 27252415
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Programmed death-1 receptor (PD-1) and PD-ligand-1 (PD-L1) expression in non-small cell lung cancer and the immune-suppressive effect of anaerobic glycolysis.
    Giatromanolaki A; Koukourakis IM; Balaska K; Mitrakas AG; Harris AL; Koukourakis MI
    Med Oncol; 2019 Jul; 36(9):76. PubMed ID: 31342270
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune response in breast cancer brain metastases and their microenvironment: the role of the PD-1/PD-L axis.
    Duchnowska R; Pęksa R; Radecka B; Mandat T; Trojanowski T; Jarosz B; Czartoryska-Arłukowicz B; Olszewski WP; Och W; Kalinka-Warzocha E; Kozłowski W; Kowalczyk A; Loi S; Biernat W; Jassem J;
    Breast Cancer Res; 2016 Apr; 18(1):43. PubMed ID: 27117582
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor mutational burden and immune infiltrates in renal cell carcinoma and matched brain metastases.
    Steindl A; Alpar D; Heller G; Mair MJ; Gatterbauer B; Dieckmann K; Widhalm G; Hainfellner JA; Schmidinger M; Bock C; Müllauer L; Preusser M; Berghoff AS
    ESMO Open; 2021 Apr; 6(2):100057. PubMed ID: 33588158
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased ERBB2 Gene Copy Numbers Reveal a Subset of Salivary Duct Carcinomas with High Densities of Tumor Infiltrating Lymphocytes and PD-L1 Expression.
    Chatzopoulos K; Collins AR; Sotiriou S; Keeney MG; Visscher DW; Rivera M; Schembri-Wismayer DJ; Lewis JE; Greipp PT; Sukov WR; Chintakuntlawar AV; Price KA; Garcia JJ
    Head Neck Pathol; 2020 Dec; 14(4):951-965. PubMed ID: 32350809
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Measuring multiple parameters of CD8+ tumor-infiltrating lymphocytes in human cancers by image analysis.
    Steele KE; Tan TH; Korn R; Dacosta K; Brown C; Kuziora M; Zimmermann J; Laffin B; Widmaier M; Rognoni L; Cardenes R; Schneider K; Boutrin A; Martin P; Zha J; Wiestler T
    J Immunother Cancer; 2018 Mar; 6(1):20. PubMed ID: 29510739
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic value of CD103
    Smith JD; Bellile EL; Ellsperman SE; Heft-Neal ME; Mann JE; Birkeland AC; Hoesli RC; Swiecicki PL; Worden FP; Schonewolf C; Shah JL; Mierzwa ML; Rosko AJ; Stucken CL; Chinn SB; Shuman AG; Casper KA; Malloy KM; Prince MEP; Wolf GT; Thomas DG; McHugh JB; Chad Brenner J; Spector ME
    Oral Oncol; 2022 Dec; 135():106226. PubMed ID: 36323071
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correlation between PD-L1 expression of the tumour cells and lymphocytes infiltration in the invasive front of urothelial carcinoma.
    Chen X; Chen H; Lin R; Li Y; Guo Y; Chen Q; Zhang Y; Cai G; Hu M; Chen G
    J Clin Pathol; 2023 Dec; 77(1):61-67. PubMed ID: 36319076
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic significance of PD-1/PD-L1 expression in uveal melanoma: correlation with tumor-infiltrating lymphocytes and clinicopathological parameters.
    Singh L; Singh MK; Kenney MC; Jager MJ; Rizvi MA; Meel R; Lomi N; Bakhshi S; Sen S; Kashyap S
    Cancer Immunol Immunother; 2021 May; 70(5):1291-1303. PubMed ID: 33136179
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinicopathologic implications of CD8
    Zou MX; Guo KM; Lv GH; Huang W; Li J; Wang XB; Jiang Y; She XL
    Cancer Immunol Immunother; 2018 Feb; 67(2):209-224. PubMed ID: 29051990
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessing the relationship between tumor-infiltrating lymphocytes and PD-L1 expression in triple negative breast cancer: Identifying optimal TILs cut-off value for pathologic reporting.
    Suwannaphoom K; Soontornsit S; Wiwatwarayos K; Seneetuntigul P; Julimasart P
    Ann Diagn Pathol; 2024 Jun; 70():152294. PubMed ID: 38513466
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluating the significance of density, localization, and PD-1/PD-L1 immunopositivity of mononuclear cells in the clinical course of lung adenocarcinoma patients with brain metastasis.
    Téglási V; Reiniger L; Fábián K; Pipek O; Csala I; Bagó AG; Várallyai P; Vízkeleti L; Rojkó L; Tímár J; Döme B; Szállási Z; Swanton C; Moldvay J
    Neuro Oncol; 2017 Aug; 19(8):1058-1067. PubMed ID: 28201746
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of tumor-infiltrating CD8+ T cells, PD1/PD-L1 axis, and expression patterns of HLA class I on the prognosis of patients with malignant pleural mesothelioma who underwent extra-pleural pneumonectomy.
    Okita R; Mimura-Kimura Y; Kawamoto N; Yamamoto N; Umeda M; Okada M; Inokawa H; Mimura Y; Murakami T; Nakata M; Okabe K
    Cancer Immunol Immunother; 2023 Apr; 72(4):865-879. PubMed ID: 36115921
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genomic alterations affecting tumor-infiltrating lymphocytes and PD-L1 expression patterns in triple-negative breast cancer.
    Wang H; Ding XH; Liu CL; Xiao Y; Shui RH; Li YP; Chen C; Yang WT; Liu S; Chen CS; Shao ZM; Jiang YZ
    J Natl Cancer Inst; 2023 Dec; 115(12):1586-1596. PubMed ID: 37549066
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The prevalence and prognostic impact of tumor-infiltrating lymphocytes in uterine carcinosarcoma.
    da Silva JL; de Albuquerque LZ; Rodrigues FR; de Mesquita GG; Chaves CBP; Bonamino MH; de Melo AC
    BMC Cancer; 2021 Dec; 21(1):1306. PubMed ID: 34876047
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor-infiltrating lymphocytes predict response to chemotherapy in patients with advance non-small cell lung cancer.
    Liu H; Zhang T; Ye J; Li H; Huang J; Li X; Wu B; Huang X; Hou J
    Cancer Immunol Immunother; 2012 Oct; 61(10):1849-56. PubMed ID: 22456757
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relationship of tumor PD-L1 (CD274) expression with lower mortality in lung high-grade neuroendocrine tumor.
    Inamura K; Yokouchi Y; Kobayashi M; Ninomiya H; Sakakibara R; Nishio M; Okumura S; Ishikawa Y
    Cancer Med; 2017 Oct; 6(10):2347-2356. PubMed ID: 28925087
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Frequent expression of CD45RO memory T cell marker as well as low to high expression of PD-1 and PD-L1 inhibitory molecules in seminoma and dysgerminoma.
    Farahani H; Dehghanian AR; Khademolhosseini A; Haghshenas MR; Erfani N
    J Reprod Immunol; 2024 Feb; 161():104184. PubMed ID: 38171036
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.